news
Pfizer and BioNTech may supply EU with 200 million doses of COVID-19 vaccine
The companies and European Commission will soon enter contract negotiations for the supply of their investigational COVID-19 vaccine candidate BNT162b2.
List view / Grid view
Viruses
news
COVID-19 vaccine tablet induces systemic and mucosal immune responses
The researchers suggest inducing a mucosal immune response may be crucial to protect against SARS-CoV-2 infection and that the tablet formulation could overcome several major challenges associated with injectable vaccines.
news
Biopharma pledges to uphold scientific integrity in COVID-19 vaccine development
Nine biopharma CEOs pledged to make the integrity of the scientific process and sufficient supply priorities in the development of COVID-19 vaccines.
news
Russia’s Sputnik V COVID-19 vaccine safely elicits an antibody response, reports paper
Preliminary data from Phase I/II trails evaluating the vaccine reveal 100 percent of participants had a humoral and cellular response, with no serious adverse events reported.
news
Sanofi and GSK initiate Phase I/II trial of COVID-19 vaccine candidate
The trial will evaluate the safety, tolerability and immunogenicity of the duo’s COVID-19 recombinant protein-based vaccine candidate in 440 healthy US participants.
news
Hydrocortisone steroid improves COVID-19 patient chance of recovery, study shows
A trial has shown that COVID-19 patients treated with the steroid hydrocortisone had a 93 percent chance of a better outcome from the coronavirus.
article
In vitro diagnostics and the coronavirus pandemic
Liz Thorn outlines the benefits that in vitro diagnostics can bring to the world in light of the current COVID-19 pandemic.
news
Canadian government strikes deals with Janssen and Novavax for COVID-19 vaccines
The Canadian government has agreed that Janssen will supply the country with 38 million doses of its COVID-19 vaccine, while Novavax has agreed to supply 76 million doses if its vaccine.
news
FSD Pharma applies to FDA for trial testing FSD201 in COVID-19 patients
The Investigational New Drug Application (IND) is for a Phase II trial evaluating the safety and efficacy of FSD201 (ultramicronized PEA) in hospitalised COVID-19 patients.
news
IL-6 signalling blockade alleviates severe COVID-19 symptoms
Scientists have shown that treating COVID-19 patients with severe respiratory complications with an IL-6 signalling inhibitor improved their symptoms.
news
Phase III testing of AstraZeneca’s AZD1222 vaccine has begun in the US
The clinical study will evaluate the efficacy of AZD1222, a COVID-19 vaccine candidate, in preventing symptomatic COVID-19 at 80 sites across the US.
news
FDA expands emergency use authorisation for remdesivir to treat all COVID-19 patients
The FDA has expanded the Emergency Use Authorisation for Veklury (remdesivir) to treat all hospitalised patients with COVID-19.
article
A glimpse at how Novartis’ manufacturing and supply organisation responded to COVID-19
The rapid evolution of the COVID-19 situation has created significant barriers to normal operations, from locking down borders to the imposition of restrictions on trade and export – not to mention a surge in demand for many common medicines. Each of these events in isolation can affect production and supply,…
article
How digitalisation can help pharma weather the COVID-19 storm
Andrew Dunbar outlines five digital technologies that can help pharma function to the best of its abilities over the course of the COVID-19 pandemic.
news
Further £8.4 million in funding given to UK researchers studying immune response to COVID-19
The funding is being split across three research projects that will hopefully improve the treatment of COVID-19 and inform the development of vaccines and therapeutics.
